KNBIF (Kane Biotech) Selling and Marketing Expense: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kane Biotech Selling and Marketing Expense?

Kane Biotech KNBIF +10.83% Selling and Marketing Expense is $0.00 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. Kane Biotech's Selling and Marketing Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Kane Biotech Selling and Marketing Expense Related Terms

Kane Biotech Selling and Marketing Expense Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Selling and Marketing Expense Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kane Biotech Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling and Marketing Expense of $0.00 Mil mean?
Kane Biotech (KNBIF) has a Selling and Marketing Expense of $0.00 Mil as of Mar. 2026. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Kane Biotech and its competitors.
Is Kane Biotech's Selling and Marketing Expense too high?
Kane Biotech's current Selling and Marketing Expense is $0.00 Mil.
How does Kane Biotech's Selling and Marketing Expense compare to VRTX and REGN?
Kane Biotech's Selling and Marketing Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling and Marketing Expense for a Biotechnology company?
A good Selling and Marketing Expense depends on the Biotechnology industry context. However, Selling and Marketing Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling and Marketing Expense mean?
A high Selling and Marketing Expense can signal that a stock is expensive relative to its fundamentals. Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. View historical data on Kane Biotech and its competitors. Kane Biotech's current Selling and Marketing Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Selling and Marketing Expense of $0.00 Mil. The current Selling and Marketing Expense is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling and Marketing Expense calculated?
Selling and Marketing Expense is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Selling and Marketing Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.